The Present Ease vs. The Future Safeguard: A Qualitative Comparison of Patient Experiences with Naproxen and Methotrexate in Rheumatoid Arthritis

Rheumatoid arthritis is a systemic autoimmune disease characterized by an erroneous immune response against the synovial membrane lining the joints. This attack induces inflammation and swelling, culminating in the progressive erosion of cartilage and bone. This study investigates the lived benefits for patients utilizing two pharmacologically distinct agents: naproxen, an anti-inflammatory, and methotrexate, a cornerstone disease-modifying antirheumatic drug (DMARD). Through a five-month, qualitative-dominant analysis of ۵۲ patients, we documented a clear dichotomy in therapeutic outcomes. The naproxen cohort reported rapid, tangible liberation from pain and stiffness, reduced swelling and morning dryness, describing a restored ability to engage in daily life with minimal disruption. Digestive problems were also reported in these patients. Conversely, patients on methotrexate narrated a different outcome—one of gradual but foundational change. Their primary benefit was a significant enhancement in joint mobility, physical function, and range of motion.While naproxen offered a powerful echo of normalcy, methotrexate provided reduced pain and swelling. Users of methotrexate reported that their range of motion and joint function improved significantly, and ultimately the progression of their disease slowed or stopped. In conclusion, naproxen is not considered a disease-modifying drug and is only used as a supplement for rapid relief of pain and stiffness in the joints. However, methotrexate is much more effective and widely used than naproxen and has more effective and safe results in the treatment of rheumatoid arthritis.

کلیدواژه ها:

: Rheumatoid Arthritis ، Methotrexate ، Naproxen ، Disease Modification ، Autoimmune Disease